

DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA AND CLL

Ian W. Flinn, M.D., Ph.D.

Director, Lymphoma Program Sarah Cannon Research Institute Nashville, Tennessee

Disclosures

- Verastem
- Infinity
- TG
- Gilead
- Kite
- Unum
- Genentech
- Roche
- Celgene
- Arqule
- Beigene
- Trillium
- Seatle Genetics
- Janssen
- Pharmacyclics
- Abvie
- Forty Seven

On Targets Effects of Inhibition of PI3K

On target effects of PI3K- δ inhibition


- Potent reduction of proliferation of malignant B cells (e.g. CLL)
 - Peluso (2014) Blood <u>124</u>:328; Balakrishnan (2015) Leukemia <u>29</u>:1811
- Inhibition of CLL cell egress from circulation into spleen
 - Chen (2015) ASH presentation



On target effects of PI3K-*γ* **inhibition**

- Inhibition of CD4+ T cells that enable CLL cell survival
 - Chen (2015) ASH presentation
- Inhibition of M2 macrophages that support CLL/FL cell survival
 - Kaneda (2016) Nature <u>539</u>:437; De Henau (2016) Nature <u>539</u>:443

DUVELISIB HEMATOLOGICAL MALIGNANCIES PHASE 1 STUDY (IPI-145-02)



Study IPI-145-02 (Phase 1): EFFICACY

overall response rate in R/R & TN CLL

	n ^a	CR n (%)	PR n (%)	SD ^b n (%)	PD n (%)	ORR n (%)
R/R, All doses	52	1 (2)	29 (56)	21 (40)	1 (2)	30 (58)
R/R, up to 25 mg BID	30	1 (3)	16 (53)	12 (40)	1 (3)	17 (57)
Unmutated IGHV	20	1 (5)	11 (55)	8 (40)	0	12 (60)
TP53 mt / del(17p)	15	1 (7)	6 (40)	7 (48)	1 (7)	7 (48)
Treatment-Naïve, 25 mg BID	17 ^c	0	15 (88)	2 (12)	0	15 (88)
TP53 mt /del(17p)	9	0	8 (89)	1 (11)	0	8 (89)

a: Includes efficacy evaluable patients only = at least one response assessment or PD without a response assessment

b: Stable disease includes patients with PR + lymphocytosis

c: 1 patient withdrew consent prior to the first efficacy assessment at Cycle 3 Day 1, and was not in the efficacy evaluable population

R/R CLL: 57% ORR by iwCLL, including 1 CR


• Median time to iwCLL response = 1.9 months

TN CLL: 88% ORR by iwCLL

- Median time to iwCLL response = 3.7 months
- 7 of 15 (47%) responses occurred by the first assessment (Cycle 3 Day 1)

Study IPI-145-02 (Phase 1): PD Duvelisib pharmacodynamics in CLL in R/R CLL


Single dose induces rapid inhibition of PI3K signaling, with no dose-dependent differences observed



Source: Flinn et al., Blood 2018 R/R – Relapsed/Refractory

EARLY SIGNALS OF ACTIVITY IN T CELL LYMPHOMA SUPPORTIVE OF FURTHER CLINICAL INVESTIGATION


T CELL LYMPHOMA COHORT IN COMPLETED PHASE 1



- Early evidence of activity in Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell lymphoma (PTCL) with monotherapy duvelisib up to 75 mg BID
- Adverse events were generally Grade 1-2, reversible, and clinically manageable

CR: Complete Response; **PR**: Partial Response **ORR**: Overall Response Rate, CR + PR Progressive disease (PD): CTCL 6 of 18 patients, PTCL 6 of 15 patients


Phase 2 trial to confirm activity of duvelisib monotherapy inPRIMOrelapsed/refractory PTCL



Goal: Establish optimal dose and confirm monotherapy activity

Trial design details:

- At least one prior therapy for PTCL; for CD30+ ALCL, patients must have failed or are ineligible or intolerant to brentuximab vedotin
- Intra-patient dose escalation in Cohort 1 is allowed




DYNAMO[™] Met primary endpoint of ORR by IRC in double refractory iNHL patients at final analysis

Primary endpoint:

• ORR by IRC at per-protocol final analysis: (p=0.0001)

Secondary endpoints:


- Median PFS on duvelisib: 9.0 months
- Median DOR: 10 months



Source: Zinzani et al., ICML 2017


DYNAMO Progression-Free Survival and Overall Survival per IRC






Source: Zinzani et al., ICML 2017

DYNAMO[™] 88% of patients in the DYNAMO[™] study had reduction in target lymph nodes by IRC



Source: Zinzani et al., ICML 2017

YNAMO



• Few discontinuations due to severe AEs of interest

• Serious opportunistic infections < 4%: PCP (unconfirmed) (n=1); CMV (n=2); fungal pneumonia (n=2)

• Deaths attributed to treatment (n=6)* *colitis (n=1): toxic epidermal necrolysis/sensis syndrome (n=1): drug reaction/eosinophilia/systemic symptoms (n=1): pneumonitis/pneumonia (n=1): viral infection (n=1): septic shock (n=1):

Source: Zinzani et al., ICML 2017

DYNAMO[™] Data supporting FL accelerated approval

Efficacy in Patients with Relapsed or Refractory FL

Overall Response Rate (ORR) assessed by IRC

Endpoint	FL	
	N = 83	
ORR, n (%) ^a	35 (42%)	
95% CI	(31, 54)	
CR, n (%)	1 (1%)	
PR, n (%)	34 (41%)	
Duration of response		
Range, months	0.0 ⁺ to 41.9 ⁺	
Patients maintaining response at 6 months, n/N (%)	15/35 (43%)	
Patients maintaining response at 12 months, n/N (%)	6/35 (17%)	

Abbreviations: CI = confidence interval; CR = complete response; IRC = Independent Review Committee; ORR = overall

response rate; PR = partial response

^a Per IRC according to Revised International Working Group criteria

⁺ Denotes censored observation

Source: Copiktra USPI, 2018

Duvelisib is approved for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. Accelerated approval was granted in this indication based on overall response rate (ORR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

For full prescribing and safety information, please refer to the Package Insert and Important Safety Information available at www.COPIKTRA.com.


DYNAMO[™] Study conclusions

- Duvelisib monotherapy is clinically active in double refractory iNHL
 - ORR of 47% per IRC (p=0.0001)
 - 88% of patients had tumor reduction
 - Responses were durable (median 10 months)
- Duvelisib has a well-characterized and manageable safety profile observed to date
- The DYNAMO study showed that duvelisib monotherapy has a favorable benefit-risk profile in refractory iNHL patients, and may represent an important treatment option in this population



Source: Zinzani et al., ICML 2017

DUO[™] A phase 3 randomized study in relapsed/refractory CLL/SLL



Response per modified iwCLL/IWG Criteria **

- Assessed by independent review committee (IRC)
- o Cycle 3 (C3), C5, C7, C11, C15, C19, every 6 months thereafter
- CT scan, CBC, disease related symptoms, BM biopsy ***
- Survival assessment every 6 months

Endpoints


- PFS (primary)
- ORR, DOR, OS (secondary)
- Safety (AEs and lab abnormalities)



Adapted from: Flinn et al.,

ASH 2017


- * Patients may have stopped treatment at C18 for CR/PR >3 months at discretion of Investigator
- ** Lymphocytosis not considered disease progression; PR = 2 Group A and 1 Group B Criteria
- *** Required for confirmation of CR/CRi



DUO Met primary endpoint of PFS

	DUV	OFA	
Median PFS (Months)	13.3	9.9	
95% CI	12.1, 16.8	9.2, 11.3	
Hazard ratio	0.52		
p-value	< 0.0001		

Investigator Assessment



	DUV	OFA
Median PFS (Months)	17.6	9.7
95% CI	15, 22	9, 11
Hazard ratio	0.4	0
p-value	< 0.00	001

• 89 patients on OFA arm received duvelisib in crossover study, achieving an ORR of 73% and a median PFS of 15 months per Investigator assessment

99

ď

bility



DUO[™] Duvelisib maintained PFS advantage in all subgroups analyzed

	DUV n	OFA n	Favors Duvelisib Favors Ofatumumak	HR	
Overall –	160	159	H O -I	0.52	
17p deletion –	33	44		0.41	
No 17p deletion –	111	102	⊢ o − I	0.55	
17p del and/or <i>TP53</i> mutation –	48	52	⊢ o − I	0.40	
No 17p del and/or <i>TP53</i> mutation –	83	84	⊢⊖−−∣	0.63	
Refractory/Early Relapse -	25	36	⊢ 	0.51	
No Refractory/Early Relapse -	135	123	⊢ o − I	0.53	
Gr. 4 Cytopenia at Baseline –	8	10	l o —−l	0.14	
No Gr. 4 Cytopenia at Baseline -	152	149	⊢ o I	0.54	
Male –	96	95	H o I	0.61	
Female –	64	64	⊢ o − I	0.44	
Age < 65 years –	48	58	H o I	0.47	
Age ≥ 65 years –	112	105	⊢ o − I	0.56	
Prior Anticancer Therapy < 12 Months –	52	63	⊢ o − I	0.40	
Prior Anticancer \geq 12 Months –	107	96	⊢ o − I	0.59	
L			I I I I I 0.0 0.5 1.0 1.5 2.0 2	1.5	
		Hazard Ratio (95% CI)			

DUO[™] Significantly higher ORR with duvelisib per IRC




85.0% 90 80 73.8% DUV OFA 70 Lymph node response: CR 0.6% 0.6% \geq 50% decrease in the SPD of Percen 60 target lymph nodes PRwL 0.6% 0 from baseline 45.3% 50 PR p-value < 0.0001 72.5% 44.7% p-value < 0.0001 40 30 15.7% 20 10 0 DUV OFA OFA DUV

ORR in patients with 17p deletion: duvelisib 70% vs OFA 43% (p=0.0182)



Lymph Node Response Rate


DUO[™] AEs of special interest infrequently led to duvelisib discontinuation



- Severe opportunistic infections (6%): bronchopulmonary aspergillosis (n=4), fungal infection (n=2), *Pneumocystis jiroveci* pneumonia (n=2)*, and cytomegalovirus colitis (n=1)
 - No severe Herpes zoster infections
- Treatment-related AEs leading to death (n=4): general health deterioration (n=1); pneumonia staphylococcal (n=2); sepsis (n=1)

*Neither patient on prophylaxis at the time of the event

DUO Crossover Extension Study Progression-Free Survival Per Investigator Assessment



Source: Kuss et al., ASCO 2018



Efficacy supporting full approval in CLL/SLL

Greater benefit/risk for patients receiving two or more prior therapies

Efficacy in CLL or SLL After at Least Two Prior Therapies

Outcome per IRC	Duvelisib N = 95	Ofatumumab N = 101	
PFS			
Number of events, n (%)	55 (58%)	70 (69%)	
Progressive disease	44	62	
Death	11	8	
Median PFS (SE), months ^a	16.4 (2.1)	9.1 (0.5)	
Hazard Ratio (SE), ^b Duvelisib/ofatumumab	0.40 (0.2)		
Response rate			
ORR n (%) ^c	74 (78%)	39 (39%)	
CR	0 (0%)	0 (0%)	
PR	74 (78%)	39 (39%)	
Difference in ORR, % (SE)	39% (6.4)		

Abbreviations: CI = confidence interval; CR = complete response; IRC = Independent Review

Committee; PFS = progression-free survival; PR = partial response; SE = standard error

^a Kaplan-Meier estimate


^b Standard Error of ln(hazard ratio) = 0.2

^c IWCLL or revised IWG response criteria, with modification for treatment-related lymphocytosis

Duvelisib is approved for the treatment of adult patients with relapsed or refractory CLL or SLL after at least two prior therapies.

For full prescribing and safety information, please refer to the Package Insert and Important Safety Information available at www.COPIKTRA.com.

Kaplan-Meier Curve of PFS per IRC In Patients with at Least 2 Prior Therapies



Source: Copiktra USPI, 2018

Conclusions:

- Duvelisib monotherapy is clinically active in double refractory iNHL
 - ORR of 47% per IRC (p=0.0001)
 - o 88% of patients had tumor reduction
 - o Responses were durable (median 10 months)
- DUO met the primary endpoint for PFS: duvelisib monotherapy achieved significant improvement in PFS vs OFA
 - PFS per investigator response assessment significantly favored duvelisib vs OFA (17.6 m vs 9.7 m; p < 0.0001)
 - $\,\circ\,\,$ Similar benefit in CLL/SLL patients with 17p deletion
 - Duvelisib achieved significant improvement in ORR vs OFA (74% vs 45%; p < 0.0001) per iwCLL/IWG
 - Duvelisib significantly reduced lymph node burden > 50% in most patients vs OFA (85% vs 16%)
- Duvelisib has a well-characterized and manageable safety profile observed to date
- Duvelisib is an important new treatment option for patients with CLL/SLL and follicular Lymphoma with 2 prior therapies